A Systematic Review and Meta-analysis of the Prevalence of Thrombosis and Bleeding at Diagnosis of Philadelphia-negative Myeloproliferative Neoplasms

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Mar 2

PMID 30819138

Citations 65

Authors

Tarinee Rungjirajittranon

Weerapat Owattanapanich

Patompong Ungprasert

Noppadol Siritanaratkul

Theera Ruchutrakool

Affiliations

Soon will be listed here.

Abstract

Background: Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most patients with MPN are asymptomatic at diagnosis although some of them suffer from constitutional symptoms. Thrombosis and bleeding can also be one of the initial manifestations although the reported prevalence varied considerably across the studies. This systematic review and meta-analysis was conducted with the aims to better understand the prevalence and characteristics of thrombosis and bleeding among patients with newly-diagnosed MPN.

Methods: Using a search strategy that included the terms for myeloproliferative neoplasms, thrombosis, and bleeding, two investigators independently searched for published articles indexed in the MEDLINE and EMBASE databases from inception to August 2018. The pooled prevalence was calculated using the DerSimonian-Laird random-effects model with a double arcsine transformation.

Results: A total of 29 cohort studies (8 prospective and 21 retrospective) with 13,436 patients with MPN were included into this meta-analysis. At diagnosis, the pooled prevalence of overall thrombosis among patients with MPN was 20.0% (95% CI, 16.6-23.8%; I 96%), with the pooled prevalence of arterial thrombosis of 16.2% (95% CI, 13.0-20.0%; I 95%) and the pooled prevalence of venous thrombosis of 6.2% (95% CI, 4.9-7.8%; I 89%). Common thrombotic events included cerebrovascular disease/transient ischemic attack, coronary heart disease, and deep venous thrombosis. The pooled prevalence of hemorrhagic complications among patients who were newly diagnosed with MPN patients was 6.2% (95% CI, 5.0-7.8%; I 85%). Common sites of bleeding included gastrointestinal, mucosal, and cutaneous bleeding.

Conclusions: Thrombosis and bleeding are common initial manifestations of MPN. Investigations for MPN should be considered for patients who present with unexplained thrombosis or abnormal bleeding.

Citing Articles

Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety.

Dunn R, Long E, Gagnon L, Harrison C, Yang Y, OSullivan J EJHaem. 2025; 6(1):e70000.

PMID: 39944793 PMC: 11815325. DOI: 10.1002/jha2.70000.

Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.

Barbui T, Ghirardi A, Carobbio A, De Stefano V, Rambaldi A, Tefferi A Blood Cancer J. 2024; 14(1):188.

PMID: 39455571 PMC: 11512069. DOI: 10.1038/s41408-024-01169-6.

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms.

Cvetkovic M, Arsenovic I, Smiljanic M, Sobas M, Bogdanovic A, Lekovic D Ann Hematol. 2024; 103(11):4545-4556.

PMID: 39331155 DOI: 10.1007/s00277-024-06023-0.

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.

Leiva O, Liu O, Zhou S, How J, Lee M, Hobbs G Curr Treat Options Oncol. 2024; 25(10):1257-1267.

PMID: 39278999 DOI: 10.1007/s11864-024-01255-8.

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.

Breccia M, Palandri F, Polverelli N, Caira M, Berluti M, Palumbo G Front Oncol. 2024; 14:1382872.

PMID: 39114304 PMC: 11303153. DOI: 10.3389/fonc.2024.1382872.

References

Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R . Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2006; 109(6):2310-3. DOI: 10.1182/blood-2006-09-046342. View

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka H, Mullauer L . Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012; 87(7):669-72. DOI: 10.1002/ajh.23217. View

Zhou D, Chen W, Cheng H, Qiao J, Zhu L, Li Z . Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia. Leuk Res. 2018; 69:1-6. DOI: 10.1016/j.leukres.2018.03.013. View

Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N . Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016; 9:18. PMC: 4779229. DOI: 10.1186/s13045-016-0242-9. View

Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J . High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015; 26(5):344-7. DOI: 10.1016/j.ejim.2015.03.009. View

Mathes T, Kuss O . A comparison of methods for meta-analysis of a small number of studies with binary outcomes. Res Synth Methods. 2018; 9(3):366-381. DOI: 10.1002/jrsm.1296. View

Jensen M, de Nully Brown P, Nielsen O, Hasselbalch H . Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000; 65(2):132-9. DOI: 10.1034/j.1600-0609.2000.90236.x. View

Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P . Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999; 105(3):618-25. DOI: 10.1046/j.1365-2141.1999.01399.x. View

Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi A, Fabris F . Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol. 2017; 96(8):1297-1302. DOI: 10.1007/s00277-017-3040-8. View

10.

Hintermair S, Zwickl-Traxler E, Pecherstorfer M, Singer J . Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015. Oncotarget. 2018; 9(9):8450-8462. PMC: 5823561. DOI: 10.18632/oncotarget.23879. View

11.

Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E . Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000; 85(10):1011-8. View

12.

Spivak J . Myeloproliferative Neoplasms. N Engl J Med. 2017; 376(22):2168-2181. DOI: 10.1056/NEJMra1406186. View

13.

Martin K . Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis. Curr Hematol Malig Rep. 2017; 12(5):389-396. DOI: 10.1007/s11899-017-0400-3. View

14.

Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda J . Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999; 13(2):150-4. DOI: 10.1038/sj.leu.2401270. View

15.

Vardiman J . Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin Diagn Pathol. 2003; 20(3):154-79. DOI: 10.1016/s0740-2570(03)00025-x. View

16.

Xu J, Lupu F, Esmon C . Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010; 30(1):5-6, 8-9. View

17.

Elliott M, Pardanani A, Lasho T, Schwager S, Tefferi A . Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010; 95(10):1788-91. PMC: 2948107. DOI: 10.3324/haematol.2010.025064. View

18.

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

19.

Kc D, Falchi L, Verstovsek S . The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017; 96(10):1595-1604. PMC: 5693670. DOI: 10.1007/s00277-017-3099-2. View

20.

Angona A, Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, Garcia-Pallarols F, Longaron R . [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients]. Med Clin (Barc). 2014; 144(6):247-53. DOI: 10.1016/j.medcli.2014.04.029. View